**Suppl. Table 2. treatment-emergent-adverse-events**

|  |  |  |
| --- | --- | --- |
| System Organ Class (SOC) | Preferred term | Frequency (n) (%; 95% CI)  (N = 30) |
| Gastrointestinal Disorders | Abdominal pain  Nausea | 3 (10%; 3.5 -25.5%)  3 (10%; 3.5 -25.5%) |
| General Disorders and Administration Site Conditions | Fatigue | 4 (13.3%; 5.3 – 29.7%) |
| Nervous System Disorders | Headache | 3 (10%; 3.5 -25.5%) |
| Skin and Subcutaneous Tissue Disorders | Pruritus/ skin rash | 2 (6.7%; 1.8 – 21.3% ) |
| *Total number of patients with adverse events* |  | 8 (26.7%; 14.2 – 44.4%) |
| *Total adverse events* |  | 15 (50%; 33.1 – 66.8%) |
| *Total Serious event/death* |  | 0 |
| *Total Severe ( ≥ grade 3)* |  | 0 |

## Data are n/N (%) in ITT patients